Federal Judge Blocks Trump Administration's Move to End Temporary Protected Status for Somali Immigrants 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
Middle East War Rattles Global Markets as Oil Tops $100 and Dollar Surges 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Oil Prices Plunge Over 6% as Middle East Ceasefire Hopes Ease Supply Fears 
U.S. Appeals Court Strikes Down FTC Order Against TurboTax "Free" Advertising 
9 Tips for Avoiding Tax Season Cyber Scams 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Microsoft Backs Anthropic in Legal Fight Against Pentagon's AI Blacklist 
Estée Lauder Sues Jo Malone Over Trademark Dispute Involving Zara 
Japan Eyes Oil Futures Intervention to Stabilize Yen Amid Middle East Crisis 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
